Nasdaq Zvra News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq zvra. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Zvra Today - Breaking & Trending Today

Maxim Group Boosts Zevra Therapeutics (NASDAQ:ZVRA) Price Target to $18.00

Zevra Therapeutics (NASDAQ:ZVRA – Free Report) had its price objective boosted by Maxim Group from $12.00 to $18.00 in a report published on Tuesday morning, Marketbeat reports. The firm currently has a buy rating on the stock. A number of other research firms also recently commented on ZVRA. William Blair reissued an outperform rating on […] ....

United States , William Blair , Cantor Fitzgerald , Maxim Group , Mirae Asset Global Investments Co , Janney Montgomery Scott , Stratos Wealth Partners , Kingsview Wealth Management , Zevra Therapeutics Inc , Zevra Therapeutics , Free Report , Wealth Partners , Asset Global Investments , Wealth Management , Get Free Report , Ligand Activated Therapy , Zevra Therapeutics Daily , Nasdaq Zvra , Boost Price Target ,

FY2024 EPS Estimates for Zevra Therapeutics, Inc. Decreased by Analyst (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Free Report) – Analysts at William Blair decreased their FY2024 earnings per share (EPS) estimates for Zevra Therapeutics in a research note issued on Wednesday, March 27th. William Blair analyst T. Lugo now forecasts that the company will earn ($1.50) per share for the year, down from their prior estimate […] ....

United States , William Blair , Commonwealth Equity Services , Raymond James Financial Services Advisors Inc , Sg Americas Securities , Cantor Fitzgerald , City State Bank , Wealth Private Client Group , Zevra Therapeutics Inc , Zevra Therapeutics , Free Report , Zevra Therapeutic , State Bank , Equity Services , Raymond James Financial Services Advisors , Get Free Report , Ligand Activated Therapy , Zevra Therapeutics Daily , Nasdaq Zvra , Earnings Estimates ,

Zevra Therapeutics, Inc. to Post FY2024 Earnings of ($1.50) Per Share, William Blair Forecasts (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Free Report) – Investment analysts at William Blair decreased their FY2024 earnings estimates for shares of Zevra Therapeutics in a report issued on Wednesday, March 27th. William Blair analyst T. Lugo now forecasts that the company will earn ($1.50) per share for the year, down from their prior estimate of […] ....

United States , William Blair , Wealth Private Client Group , Zevra Therapeutics Inc , City State Bank , Cantor Fitzgerald , Sg Americas Securities , Raymond James Financial Services Advisors Inc , Commonwealth Equity Services , Zevra Therapeutics , Free Report , Zevra Therapeutic , Therapeutics Stock Down , State Bank , Equity Services , Raymond James Financial Services Advisors , Get Free Report , Ligand Activated Therapy , Zevra Therapeutics Daily , Nasdaq Zvra , Earnings Estimates ,

Zevra Therapeutics Announces Top-Line Data from the Phase 2

KP1077 demonstrates clinically meaningful benefits for key IH symptoms Top-line data provide key information for the design of a Phase 3 study . ....

United States , Christopher Drake , Neil Mcfarlane , Nichol Ochsner , Ignacio Guerrero Ros , Adannag Alexander , Zevra Therapeutics Inc , Us Drug Enforcement Agency , Drug Administration , Exchange Commission , Epworth Sleepiness Scale , Idiopathic Hypersomnia Severity Scale , Sleep Inertia Visual Analog Scale , Principal Investigator , Chief Executive Officer , Brain Fog , Idiopathic Hypersomnia , Orphan Drug Designation , Enforcement Agency , Private Securities Litigation Reform Act , Annual Report , Quarterly Report , Nasdaq Zvra , Zevra Therapeutics ,

Mystic Asset Management Inc. Acquires New Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Mystic Asset Management Inc. acquired a new position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 203,283 shares of the company’s stock, valued at approximately $980,000. Mystic Asset Management Inc. […] ....

United States , Zevra Therapeutics Inc , Commonwealth Equity Services , Cantor Fitzgerald , Kingsview Wealth Management , Exchange Commission , Mystic Asset Management Inc , Wealth Private Client Group , Mystic Asset Management , Zevra Therapeutics , Free Report , Asset Management , Equity Services , Wealth Management , Ligand Activated Therapy , Visit Holdingschannel , Zevra Therapeutics Daily , Nasdaq Zvra , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,